Skip to main content
OpenTrials
Completed

NCT Number: NCT01107171

Trial of Tang-min-ling Pills in the Treatment of Type 2 Diabetes

Tang-min-ling pills are made by Chinese herbs extract, and data showed they had antidiabetic effects on the experimental rats and no obvious toxicity was found.This is a randomized, doubled blind, dose-paralleled-control multi-centre clinical trial to evaluate the efficacy and safety of Tang-min-ling pills in the treatment of type 2 diabetic patients and explore the optimal dosage of Tang-min-ling pills.

Completed

Looking for future studies?

Notify Me

Key information

Age range

30 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Jilin Hospital of Integrated Traditional and Western Medicine, Changchun, China

Loading trial locations.

About this study

Two hundred and ten of overweight patients inflicted with primary diabetes mellitus who had stagnated heat of liver and stomach syndrome were recruited, which were randomly divided into 3 groups, and were given high-dosage (12g Tang-min-ling pills every time), low-dosage (6g Tang-min-ling pills every time)、placebo by 3 times every day for 12 weeks respectively. Hemoglobin A1c (HbA1c), Fasting plasma glucose (FPG)、postprandial 2 hours plasma glucose(2hPG)、syndrome、symptoms、body mass index (BMI)、waist circumference (WC) of these groups were measured and analyzed. Some safety indexes such blood and urine and stool routine examination, electrocardiogram (ECG)and liver and kidney function tests were measured and analyzed during the experiment. The treatment period is 12 week.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with primary type 2 diabetes mellitus
  • BMI ≥ 24 kg•m-2
  • 30-70 years old
  • HbA1c≥7.0%, and FPG>7.0 mmol/L, but <13.9 mmol/L or 2hPG>11.1 mmol/L
  • Informed consent has been signed
  • stagnated heat of liver and stomach syndrome according to TCM syndrome differentiation

Exclusion criteria

  • The patients accepted diabetic treatment for more than a month continuously
  • The patients were treated by drugs in 3 week before they were given test drugs
  • Diabetic ketosis, diabetic ketoacidosis or serious inflammation in a month
  • The contractive pressure >160 mmHg or diastolic pressure >100 mmHg
  • Pregnant, preparing for pregnancy or breast-feeding women
  • Mental patients
  • The patients who have serious heart, lung, liver, kidney and brain or other primary complications
  • Allergic persons
  • The patients who are attending other clinical trial
  • The patients who have serious diabetic complications
  • The patients who ever attended this clinical trial
  • Alcohol and / or psychoactive substances, drug abuse and dependency
  • The person maybe loss for some reason such as work or life condition according to the investigator's judgement
  • The lipid-lowering or antihypertensive drug dosage and category which the patients are taking couldn't be kept stable
  • The patients who are eating some drugs or health food which can affect the body weight

Treatment and study plan

Tang-min-ling pills low dosage

Drug

low dosage:6g Tang-min-ling pills every time,by 3 times every day for 12 weeks.

Other names: Tang min lin pill

Tang-min-ling pills high dosage

Drug

high dosage:12g Tang-min-ling pills every time,by 3 times every day for 12 weeks.

Other names: Tang min lin pills

Placebo

Drug

Tang-min-Ling pills analogue 6g,tid,po

Other names: Tang-min-Ling pills analogue

Primary outcomes

  1. Hemoglobin A1c (HbA1c)

    Time frame: 12 weeks after treatment

    The HbA1c was measured and analyzed twice, one is before the treatment and the other is 12 weeks aftertreatment to make a self comparison.

Secondary outcomes

  1. Fasting plasma glucose (FPG)、postprandial 2 hours plasma glucose(2hPG)、body mass index (BMI)、waist circumference (WC)

    Time frame: 12 weeks after treatment

  2. symptoms score and Chinese syndrome

    Time frame: 12 weeks after treatment

  3. The rate of adverse events,the blood and urine and stool routine examination, electrocardiogram (ECG)and liver and kidney function tests

    Time frame: 12 weeks after treatment

    The number of participants with adverse events were recorded and compared. The blood and urine and stool routine examination, electrocardiogram (ECG)and liver and kidney function tests were measured and observe the safety.

Sponsors and collaborators

Lead sponsor

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Other

Collaborators

  • Tasly Pharmaceuticals, Inc.

Registry information

Official study title

Multi-center Randomized Controled and Double Blind Trial of Tang-min-ling Pills in the Treatment of Type 2 Diabetes

Important dates

Study start
2008
Primary completion
2008
Study completion
2008
First posted
Apr 20, 2010
Registry last updated
Apr 21, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.